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INTRODUCTION
The p53 tumor suppressor gene has a critical role for regula-
tion of cell cycle, cellular growth, and maintenance of genomic
integrity (1). And it is well known that the inactivating muta-
tion of p53 is the most common genetic alteration in human
cancers including hepatocellular carcinoma (HCC) (2). The
mutational spectrum of p53 has been reported to differ in
HCCs from different geographic regions. For example, the G
to T transversion at the third position of codon 249 has been
detected very frequently, ranging from 30 to 58% of HCCs,
in southern Africa and southern China in which aflatoxin B1
is contaminated highly in food and hepatitis B virus (HBV)
infection is endemic (3-5). In contrast, few or none of the muta-
tions occur at codon 249 in low aflatoxin B1 exposure areas
(6-9). In Korea, HCC is one of the most common cancers,
HBV-related HCC constitutes about 65-70% of HCC, and
dietary exposure of aflatoxin B1 is low (10, 11). There are a
few reports, however, on the status of p53 mutation at exons
3-9 or 5-8 in HCC patients in Korea (12-14).
The missense mutations of p53 may result in biologically
altered proteins with increased stability that is easily detectable
by immunohistochemical method. However, deletion or trun-
cated proteins resulted from nonsense or frameshift mutations
are usually not detectable by immunohistochemical method,
because these proteins are very unstable in the cell, even using
antibody containing the corresponding N-terminal epitope (2).
Therefore, immunohistochemistry (IHC) will be less sensitive
in detecting mutations in tumors with high proportion of
these non-missense mutations. p53 overexpression is detected
at a higher incidence than gene mutation in human cancers
(44% vs 36%) (2).
In p53 IHC, the proportion of cells that show immunore-
activity is very important (15). Occurrence of just occasional
strongly immunoreactive cells in a tumor does not seem to
correlate with obvious molecular abnormality of p53 (16).
They may rather represent the normal working of the p53
system in which the wild-type protein accumulate in response
to spontaneous genetic errors occurring at a higher frequency
in the tumor than in the normal surrounding tissue. In p53
immunohistochemical study on HCC, the threshold value
above which the result is regarded positive has not been well
established. p53 overexpression in HCC is not always depen-
dent on p53 mutation (17). And the degree of correlation
between sequencing and IHC for detecting mutations of p53
has not been well established in human HCCs. 
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Correlation of Mutation and Immunohistochemistry of p53 in 
Hepatocellular Carcinomas in Korean People
The degree of correlation between sequencing and immunohistochemisty (IHC) for
detecting mutations of p53 has not been well established in human hepatocellular
carcinoma (HCC). We analyzed 36 HCCs from Korean people for p53 mutation
at exons 4-10 by PCR-SSCP and sequencing, and compared the results with the
IHC positivity. p53 mutations were identified in 7 out of 36 HCCs (19.4%). These
mutations were found widely throughout exons 4-8. No mutation was detected in
codon 249. Among the 7 mutations, 6 missense mutations were detected in 15
HCCs with ≥5% immunoreactive tumor cells and one nonsense mutation was in
21 HCCs with <5% immunoreactive tumor cells. The sensitivity for p53 mutation
was 85.7% (6/7), the specificity 69.0% (20/29), the predictive value of positive IHC
40.0% (6/15), and the predictive value of negative IHC 95.2% (20/21). Two mis-
sense mutations were detected in 25 cases with <10% immunoreactive tumor cells.
Predictive values of both positive IHC and negative IHC were higher in ≥5% over-
expression group than in ≥10% overexpression group or >0% overexpression
group. This study suggests that 5% immunoreactivity is a reliable immunohisto-
chemical threshold value to detect p53 mutations in HCCs and the spectrum of
p53 mutations in HCCs in Korean people is different from that of high aflatoxin B1
exposure areas.
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In this study, we determined what proportion of cells that
show immunoreactivity is a reliable immunohistochemical
threshold value to detect p53 mutations in HCCs and evaluat-
ed the spectrum of p53 mutations at exons 4-10 in 36 HCCs
from Korean people. 
MATERIALS AND METHODS
Tumor samples
Samples of 36 HCCs were obtained from 34 Korean patients
at the time of curative surgical resection at Samsung Medical
Center, Seoul, Korea, between 1999 and 2000. None of the
patients had any preoperative chemotherapy. All of these were
primary HCC tumors: 33 were from patients with a single
HCC nodule and 3 were from 1 patient with three HCC nod-
ules of Edmondson & Steiner grade I. Informed consent was
obtained from each patient. The age of patients ranged from
26 to 89 yr, with a mean age of 51.8 yr. The male-to-female
ratio was 27:7. All samples included both tumors and non-
tumorous tissues. Halves of the samples were snap-frozen in
liquid nitrogen and stored at -80℃ until DNA extraction.
The other halves were fixed in 10% formalin and embedded
in paraffin. The longest diameter of a tumor ranged from 9 to
110 mm, with a mean of 38.6 mm. The degrees of differenti-
ation of tumor cells were determined according to the Edmond-
son & Steiner’s grading system (18). There were 6 cases of
Edmondson & Steiner grade I, 11 grade II, and 19 grade III.
The nontumorous liver showed cirrhosis in 23 (67.6%) patients
and chronic hepatitis in 11 (32.4%). The etiologies of liver
disease were HBV in 27 patients, hepatitis C virus (HCV) in
3, and cryptogenic in 4. 
Immunohistochemistry
Formalin-fixed, paraffin-embedded sections of 4  m con-
taining both HCC and nontumorous liver were prepared.
Immunohistochemical study was performed using the strep-
tavidin-biotin complex method and TechMateTM 1,000 auto-
mated staining system (DakoChemmate, Glostrup, Denmark).
Primary monoclonal antibody against p53 (clone BP53-12)
was purchased from Zymed Lab Inc. (San Francisco, CA,
U.S.A.) and used at 1:80 dilution. Deparaffinized sections
were processed in 0.05 M sodium citrate buffer (pH 6.0) and
heated in a microwave oven for 10 min for antigen retrieval.
Sections were then incubated with the primary antibody for
60 min at room temperature. DAB (3,3′ -diaminobenzidine
tetrahydrochloride) was used as chromogen. Negative controls
were run simultaneously with an omission of primary anti-
body. Blocks of normal liver were prepared from 10 patients
with metastatic colonic carcinoma of the liver as control cases.
For assessment of the positivity of immunostaining for each
section, only nuclear staining was regarded as positive. We
counted tumor cells with clearly brown reaction products in
nuclei by monitoring at least 1,000 tumor cells from more
than five high power fields where positive cells were present
at a relatively uniform density. Three observers evaluated stain-
ing results independently and differences in interpretation
were resolved by consensus.
DNA extraction
Frozen tissue samples were pulverized to a powder using
a mortar and pestle precooled with liquid nitrogen, supend-
ed in lysis buffer, and treated with proteinase K. DNA was
extracted by phenol-chloroform-isoamyl alcohol as described
elsewhere (19). 
PCR-SSCP and DNA sequencing
Each of p53 exons 4-10 was amplified by PCR. The primers
and the cycling conditions for each exon are listed in Table 1.
Each PCR reaction was generally performed under standard
conditions in a 10  L reaction mixture containing 1  L of tem-
plate DNA, 0.4  M of each primer, 125  M of each dNTP,
1.5 mM MgCl2, 0.4 unit of Taq polymerase, 0.5  Ci of [32P]
dCTP (Amersham, Buckinghamshire, U.K.), and 1  L of 10
× buffer. The reaction mixture was predenatured for 12 min
at 95℃ and amplified for 35 cycles (denaturing for 30 sec at
95℃, annealing for 30 sec at 55-59℃, and extending for 30
sec at 72℃). Final extension was continued for 5 min at 72℃.
PCR products were denatured for 5 min at 95℃at a 1:1 dilu-
tion of formamide loading dye containing 95% formamide, 20
mM/L EDTA, 0.05% bromophenol blue, and 0.05% xylene
cyanol and were loaded onto a MDE gel (AT Biochem, Mal-
vern, PA, U.S.A.) with 10% glycerol. After electrophoresis,
the gels were transferred to 3-mm Whatman paper and autora-
diography was performed using Kodak X-OMAT film (East-
man Kodak, Rochester, NY, U.S.A.). For the detection of
4 (1)ATCTACAGTCCCCCTTGCCG 296 55℃
(2)GCAACTGACCGTGCAAGTCA
5 (1)GCTGCCGTGTTCCAGTTGCT 294 58℃
(2)CCAGCCCTGTCGTCTCTCCA
6 (1)GGCCTCTGATTCCTCACTGA 199 55℃
(2)GCCACTGACAACCACCCTTA
7 (1)TGCCACAGGTCTCCCCAAGG 196 56℃
(2)AGTGTGCAGGGTGGCAAGTG
8 (1)CCTTACTGCCTCTTGCTTCT 225 55℃
(2)ATAACTGCACCCTTGGTCTC
9 (1)GCCTCAGATTCACTTTTATCACC 152 56℃
(2)CTTTCCACTTGATAAGAGGTCCC
10 (1)ATACTTACTTCTCCCCCTCCTC 184 59℃
(2)AGGAAGGCAGGGGAGTAG
*(1), sense primer; (2), antisense primer.
Exon                      Primers*                      Product size   Annealing Temp.
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mutations, DNAs showing mobility shifts were cut out from
the dried gels and reamplified for 30 cycles using the same
primer set. Sequencing of the PCR products was carried out
using the cyclic sequencing kit (Perkin-Elmer, Foster City,
CA, U.S.A.) according to the manufacturer’s recommenda-
tions. All mutations were verified through triplicated exper-
iments including PCR-SSCP and sequencing analysis, which
ensured the specificity of the results.
Statistical analysis
Chi-square test was used for the statistical analysis. Two-
sided p-value of less than 0.05 was considered as statistically
significant. 
The sensitivity of p53 mutation was the percentage of IHC-
positive tumors among tumors with identified mutation. The
specificity was the percentage of IHC-negative tumors among
tumors without p53 mutation. The predictive value of positive
IHC was the percentage of IHC-positive tumors, which had
p53 mutation. The predictive value of negative IHC was the
percentage of IHC-negative tumors, which lacked p53 muta-
tion. Accuracy was the percentage of tumors correctly classified
for p53 mutation by IHC.
RESULTS 
Immunohistochemical analysis of p53
Of the 36 HCC cases, 3 had ≥50% of tumor cells stained
for p53, 8 had 10-49% of tumor cells stained for p53, 4 had
5-9% of tumor cells stained for p53, 10 had 1-4% of tumor
cells stained for p53, and 11 did not stained for p53. No nucle-
ar staining was found in nontumorous liver tissues or normal
controls. 
Fifteen out of 36 HCCs (41.7%) had ≥5% of tumor cells
stained for p53: 13 out of 27 HBsAg seropositive cases (48.1%),
1 out of 5 anti-HCV antibody seropositive cases (20%), and
1 out of 4 both HBsAg and anti-HCV antibody seronegative
cases (25%). The p53 was overexpressed more frequently in
HCCs with poorer histological grade of differentiation (Ed-
mondson I, 0%; Edmondson II, 36.3%; Edmondson III,
57.9%; p=0.039).
DNA sequencing analysis
We detected 7 somatic mutations out of 36 HCCs (19.4%)
consisting of 6 missense and 1 nonsense mutations (Table 2).
These mutations were found widely throughout exons 4-8
without any mutational hot spot. No mutation was detected
in codon 249. Two representative cases with aberrant bands
and mutations are shown in Fig. 1. Nontumorous liver tissues
from all 36 cases showed no mutation.
Mutations were found in 5 HBsAg seropositive cases, 1 anti-
HCV antibody seropositive case, and 1 both HBsAg and anti-
HCV antibody seronegative case. Mutations were frequently
found in HCCs with poorer histological grade of differentiation
(Edmondson I, 0%; Edmondson II, 18.2%; Edmondson III
26.3%; p>0.05).
Correlation of p53 mutation and p53 overexpression 
Among the 7 mutations, 6 missense mutations were detect-
ed in 15 HCCs with ≥5% immunoreactive tumor cells and
one nonsense mutation was in 21 HCCs with <5% immunore-
active tumor cells (40% vs 4.8%, p=0.027). The sensitivity
for p53 mutation was 85.7% (6/7), the specificity 69.0%
(20/29), the predictive value of positive IHC 40.0% (6/15),
the predictive value of negative IHC 95.2% (20/21), and the
accuracy 72.2% (26/36). 
No missense mutation was detected in all 21 cases with <5%
immunoreactive tumor cells but 2 missense mutations were
detected in 25 cases with <10% immunoreactive tumor cells.
10 4 111 CTG→CGG Leu→Arg Transversion HCV
11 6 194 CTT→CGT Leu→Arg Transversion -
12 5 175 CGC→CTC Arg→Leu Transversion HBV
22 5 158 CGC→CAC Arg→His Transition HBV
30 8 280 AGA→TGA Arg→Stop Transversion HBV
33 8 273 CGT→TGT Arg→Cys Transition HBV
35 6 214 CAT→CGT His→Arg Transition HBV
Exon Codon
Case
No.
Nucleotide
change
Amino acid
change
Type of 
mutation
Hepatitis* 
virus
Table 2. Summary of p53 mutations in 36 cases of hepatocel-
lular carcinoma
*HBV, HBsAg(+); HCV, anti-HCV antibody(+).
Fig. 1. PCR-SSCP of exon 6 and 8 of the p53 shows abnormally
shifted bands (arrowheads) in A (case 11) and B (case 33) (N,
normal; T, tumor). Sequencing reveals CTT→CGT at codon 194
in case 11 (C) and CGT→TGT at codon 273 in case 33 (D). 
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C D
◀
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SSCP(exon 6)
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If we regarded the p53 IHC as positive when ≥10% of tumor
cells were stained, the sensitivity for p53 mutation was 57.1%
(4/7), the specificity 75.9% (22/29), the predictive value of
positive IHC 36.4% (4/11), the predictive value of negative
IHC 88.0% (22/25), and the accuracy 72.2% (26/36). If we
regarded the p53 IHC as positive based on the presence of any
immunoreactive tumor cells, the sensitivity for p53 mutation
was 85.7% (6/7), the specificity 34.5% (10/29), the predictive
value of positive IHC 24.0% (6/25), the predictive value of
negative IHC 90.9% (10/11), and the accuracy 44.4% (16/36).
DISCUSSION
The p53 consists of 11 exons. Greenblatt et al. (2) had iden-
tified 50 studies in which sequencing of the entire coding
region of p53 in human cancers was reported. Of the 560
mutations reported in these papers, 87% were in exons 5-8
and most of the others were in exon 4 (8%) and exon 10 (4%).
Mutations outside exons 5-8 were most frequent in urinary
bladder carcinoma (28%) and HCC (24%). There have been
six studies in which sequencing of the entire coding region
of p53 in HCCs was reported (6, 17, 20-23). All of the 68
mutations reported in these papers were in exons 4-10. There-
fore, we analyzed nucleotide sequences of the p53 in exons
4-10.
The frequency of p53 mutations has been reported to differ
in HCCs from various geographic areas: 50-58% in southern
China and southern Africa, 15-32% in Japan, and 15.4% in
Germany (3, 5, 6, 8, 24). In this study, we showed that p53
mutation in HCCs in Korean people, at a frequency of 19.4%,
is not uncommon. The not uncommon frequency of p53
mutations might represent only one of the multiple steps
involved in hepatocarcinogenesis, as in other human cancers
(1). In addition, no mutation was detected at codon 249 in the
present study. This is consistent with the low prevalence of
mutations at codon 249 reported in geographic areas where
aflatoxin B1is not detectable at high levels in the diet, such as
U.S.A., Germany, France, Britain, Taiwan, Australia, Japan,
and Korea (6-9, 12-14, 25-27). This finding suggests that
factors other than aflatoxin B1 may be responsible for the p53
abnormalities in HCCs. The mutations in HCCs in low afla-
toxin exposure areas often show a wide distribution over the
highly conserved region covering exons 4-10 (6). The findings
of the present study are also in line with this observation, with
mutations scattered over exons 4-8. 
We have found that overexpression of p53 in HCCs was
correlated with the mutation of the p53 (p=0.027). However,
there was substantial discrepancy between molecular genetic
alterations in p53 and overexpression of the protein. In p53
immunohistochemical studies on HCCs, there have been
different threshold values above which the result is regarded
positive: presence of any labeled cells, 2%, 5%, 10%, or 50%
immunoreactivity (28-32). Volkmann et al. (33) regarded the
p53 IHC as positive based on the presence of any immunore-
active cells and reported that one HCC with a few immunore-
active cells had wild-type p53. Volkmann et al. (34) regarded
the p53 IHC as positive based on the presence of any immu-
noreactive cells and reported that one out of eight HCCs with
1-9% immunoreactive cells showed missense mutation of p53.
Hsia et al. (35) regarded 10% immunoreactivity as the thresh-
old value and reported that one out of four HCCs with 1-9%
immunoreactive cells showed missense mutation of p53. 
Our findings showed that HCCs with ≥5% immunore-
active tumor cells are the ones in which p53 mutations are
most frequently present. No missense mutation was detected
in all 21 cases with <5% immunoreactive tumor cells but 2
missense mutations were detected in 25 cases with <10%
immunoreactive tumor cells. Predictive values of both positive
IHC and negative IHC were higher in ≥5% overexpression
group than in ≥10% overexpression group or >0% over-
expression group. The specificity for p53 mutation in >0%
overexpression group was very low. These findings suggest
that 5% immunoreactivity is a reliable immunohistochemical
threshold value to detect p53 mutations in HCCs. It should
be noted that our findings might not be applicable to other
tumor types in which discordance between IHC and molecular
genetic analysis of p53 is more frequent.
These results suggest that 5% immunoreactivity is a reli-
able immunohistochemical threshold value to detect p53
mutations in HCCs and the spectrum of p53 mutations in
HCCs in Korean people is different from that of high aflatoxin
B1 exposure areas. 
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